SPRY

ARS Pharmaceuticals, Inc. Common Stock

4.18

USD

-0.30

-6.70%

Sep 23, 15:59 UTC -4

Closed

After-Market

4.24

+0.06

+1.34%

SPRY Earnings Reports

Positive Surprise Ratio

SPRY beat 11 of 23 last estimates.

48%

Next Report

Date of Next Report

Nov 09, 2026

Estimate for Q3 26 (Revenue/ EPS)

$43.70M

-$0.31

Implied change from Q2 26 (Revenue/ EPS)

+29.84%

-50.79%

Implied change from Q3 25 (Revenue/ EPS)

+34.46%

-40.38%

ARS Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Aug 13, 2026, SPRY reported earnings of -0.63 USD per share (EPS) for Q2 26, missing the estimate of -0.50 USD, resulting in a -25.40% surprise. Revenue reached 33.66 million, compared to an expected 31.95 million, with a 5.35% difference. The market reacted with a -7.38% price change (close before vs. close after earnings).

Looking ahead to Q3 26, -- analysts forecast an EPS of -0.31 USD, with revenue projected to reach 43.70 million USD, implying an decrease of -50.79% EPS, and increase of 29.84% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Champions Oncology, Inc.

Report Date

Sep 10, 2026 For Q1 27

Estimate

-$0.01

Actual

-$0.03

Surprise

-194.12%

PharmaCyte Biotech, Inc. Common Stock

Report Date

Sep 14, 2026 For Q1 27

Estimate

Actual

-$0.54

Surprise

FAQ

What were ARS Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, ARS Pharmaceuticals, Inc. Common Stock reported EPS of -$0.63, missing estimates by -25.4%, and revenue of $33.66M, 5.35% above expectations.

How did the market react to ARS Pharmaceuticals, Inc. Common Stock's Q2 2026 earnings?

The stock price moved down -7.38%, changed from $6.10 before the earnings release to $5.65 the day after.

When is ARS Pharmaceuticals, Inc. Common Stock expected to report next?

The next earning report is scheduled for Nov 09, 2026.

What are the forecasts for ARS Pharmaceuticals, Inc. Common Stock's next earnings report?

Based on -- analysts, ARS Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.31 and revenue of $43.70M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.